Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) today announced that it will present at the UBS Global Life Sciences Conference (September 21-23, 2009) in New York.
Sijmen de Vries, Chief Executive Officer of Pharming, will present an update on the Company and its business on Monday, September 21 at 2:00 pm Eastern Time (8:00 pm Central European Time). The live audio webcast can be accessed via the UBS website. The presentation will be available on Pharming's website after the meeting.
The conference attendees include institutional investors from the United States, Europe and Asia-Pacific. For further information on the UBS Global Life Sciences Conference, please visit www.ibb.ubs.com.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin(R) for Hereditary Angioedema and human Lactoferrin for use in food products and one product in early stage clinical development - Prodarsan(R) for Cockayne Syndrome. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, http://www.pharming.com.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.